BioMark Diagnostics Inc. (BUX.CN)

BioMark Diagnostics Inc. (BUX.CN) — VMCI valuation read

BioMark Diagnostics Inc. (BUX.CN) carries a VMCI composite of 32/100, 18 points below the Healthcare sector median of 50. Among mid-cap names, that gap places BUX.CN in the bottom third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The BUX.CN insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads BUX.CN trades at 14.0x earnings, 22% below the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 3.5x is the binding constraint on the bear case, the line to track on BioMark Diagnostics Inc.'s next 10-Q.

BUX.CN rose 3.6% over the trailing 7 days, with a -8.6% read on a 30-day basis.